The GLP-1 telehealth market is going through a correction. Eighty-five FDA warning letters. A landmark patent lawsuit and settlement. A proposal to strip compounding access from outsourcing facilities. State boards retroactively auditing prescribers. Medicare entering the market with $50/month pricing that undercuts most compounded alternatives.
Every one of these forces is pushing in the same direction: fewer platforms, higher standards, and a fundamental shift from compounded to branded medications. The platforms that survive will look very different from the ones that launched during the gold rush. The question for patients is whether your current provider is built to last — or running on borrowed time.
The Forces Driving Consolidation
Regulatory pressure
The FDA's enforcement arc — 55 warning letters in September 2025, 30 more in March 2026, DOJ referrals, and the 503B Bulks List proposal — creates a compliance cost that smaller platforms can't absorb. Each warning letter requires legal response, marketing overhaul, and potentially business model restructuring. Platforms operating on thin margins with minimal compliance infrastructure will be forced to exit or merge.
Legal exposure
The Novo Nordisk vs. Hims lawsuit established that semaglutide patent holders will enforce their rights aggressively. Semaglutide patents run until 2032. Every platform selling compounded semaglutide faces potential patent infringement liability. The settlement template — stop compounding, start distributing branded products — may be the only viable path forward for platforms that want to stay in business.
Market dynamics
The Medicare GLP-1 Bridge ($50/month for branded medications) and manufacturer pricing programs create a price floor that compounded options struggle to beat once you factor in quality, reliability, and regulatory certainty. When the branded option costs $50 for Medicare patients and $25 for commercially insured patients with savings cards, the value proposition of a $99 compounded alternative erodes.
Clinical maturation
State medical boards are raising the bar for GLP-1 telehealth prescribing. Follow-up requirements, lab monitoring expectations, informed consent documentation, and prescriber-patient relationship standards are all tightening. Platforms built for speed and volume — fast sign-up, minimal evaluation, no follow-up — are poorly positioned for a regulatory environment that demands clinical depth.
The Survival Scorecard: How to Evaluate Your Provider
Rate your current (or prospective) telehealth platform across these six dimensions:
1. LegitScript Certification
LegitScript is an independent verification service that evaluates online pharmacies and telehealth platforms for regulatory compliance. Certification isn't legally required, but it's the closest thing to an industry seal of approval. Platforms that invest in LegitScript certification signal a commitment to operating within regulatory boundaries.
2. Branded Drug Distribution
Does the platform have direct distribution agreements with Novo Nordisk (for Wegovy) and/or Eli Lilly (for Zepbound)? Post-Hims settlement, branded distribution is increasingly the baseline expectation. Platforms that can only offer compounded products face supply chain risk.
3. Lab Monitoring Infrastructure
Does the platform require baseline labs? Offer ongoing monitoring? Integrate at-home lab kits? Platforms with monitoring infrastructure are better positioned to meet tightening state requirements and deliver better clinical outcomes.
4. Follow-Up Protocols
Are follow-up visits required or merely available? At what intervals? Who conducts them — a clinician or a chatbot? Platforms with structured follow-up protocols are aligned with where state boards are heading.
5. State Licensing Compliance
Is the prescribing clinician licensed in your state? Is the pharmacy licensed and, for compounding pharmacies, properly registered (503A or 503B)? Are collaborative practice agreements in place where required? Platforms with broad, verified state coverage are less likely to face licensing disruptions.
6. Financial Stability
This is harder to assess from the outside, but look for signals: how long has the platform been operating? Do they have venture backing or established revenue? Have they been growing their team or cutting staff? A platform that shuts down mid-treatment leaves you without a prescriber, potentially without medication refills, and scrambling to establish care elsewhere.
What to Do Now
- Audit your current provider against the six criteria above. Don't wait for a disruption to discover your platform doesn't meet regulatory standards.
- Have a backup plan. Identify at least one alternative provider that scores well across all six dimensions. If your current platform goes dark, you don't want to start the provider search from zero while your medication supply runs out.
- Secure your medical records. Download or request copies of your treatment records, lab results, and prescription history from your current platform. If they shut down, accessing your records becomes exponentially harder.
- Check your insurance options. Medicare Bridge (July 2026), commercial formularies, and manufacturer savings programs may have changed your cost calculus. Branded medications through insurance may now be competitive with compounded cash-pay pricing.
- Plan for the long term. GLP-1 treatment is typically ongoing. Choose a provider that's built for years of treatment management, not just the next refill.